Investment
Features
FeesSafety
Academy
More
Pluang+

Lode Gold completes first six drill holes in expanded Fremont Gold Mine program, awaits assay results.

Market News
19 Oct 2026
Newsfile Corp
View Source
Bullish
Lode Gold completes first six drill holes in expanded Fremont Gold Mine program, awaits assay results.

Lode Gold Resources has finished the first six of 20 planned drill holes at its Fremont Gold Mine in California, expanding the campaign to 4,200 meters. These holes are part of a metallurgical drilling program to support future feasibility studies, with samples from the first two holes sent for analysis. The company is using large-diameter core drilling to gather enough material for both assays and metallurgical testing, addressing challenges from historical underground workings. Results are expected as the program continues into early 2027, marking a key phase in advancing the Fremont project.

Lode Gold's expanded drill program at Fremont Gold Mine provides context for the Basic Materials sector's market activity on Pluang as of Oct 19, 2026 18:11 WIB. Of 83 priced US stocks in this sector, 44 rose and 29 fell. Notable movers include Johnson Controls International PLC (JCI) at USD 147.46 with a 1.37% gain, Element Solutions Inc. (ESI) at USD 35.52 up 1.34%, and Franco-Nevada Corporation (FNV) at USD 240.72 down 1.23%.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
24 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
24 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
24 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
24 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
24 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App